A few stocks of ASX listed companies are indicating good long term growth potential. This is so because they are already through the initial stage and getting ready to reap the benefits. Given their market opportunity, these are potentially best growth stocks to buy now
Orthocell Limited (ASX: OCC)
Orthocell Limited (ASX: OCC) announced having achieved significant progress in expanding the market reach of its dental guided bone regeneration product, Striate+. The company, in partnership with its exclusive global distributor BioHorizons, has successfully launched Striate+ in Germany, Austria, and Switzerland, marking its entry into the lucrative DACH region. This expansion is a key milestone in BioHorizons' European market penetration strategy, targeting a share of a global market valued at over AUD 1 billion. Initial sales have been completed, and given BioHorizons’ strong presence in the region, the company anticipates rapid revenue growth.
The launch follows a surge in global demand for Striate+, driven by its 98.6% success rate in post-market clinical studies and strong endorsements from dental surgeons. The product’s ease of use, adaptability to treatment surfaces, and ability to enhance bone growth have contributed to its widespread adoption. Orthocell is also working closely with BioHorizons to accelerate expansion into new markets, particularly Brazil, where regulatory approval is expected within three months.
Orthocell’s international regulatory approvals have also strengthened its market position, with the company recently securing approval from Singapore’s Health Sciences Authority (HSA) to sell Striate+ in the region. Singapore serves as a strategic regulatory hub and a gateway to other ASEAN markets, reinforcing the company’s long-term global expansion plans. With existing approvals in the US, Europe, UK, Australia, New Zealand, and Canada, the Singapore approval further validates the high quality of Orthocell’s products and manufacturing standards.
Orthocell is well-positioned to support its commercial expansion, with approximately $32-33 million in cash reserves as of early 2025. Orthocell is targeting a 20% share of the global market for Striate+ while simultaneously advancing its regulatory efforts in multiple regions. With a robust balance sheet, increasing market penetration, and a growing demand for its regenerative medicine solutions, the company is well-positioned for sustained growth and commercial success.
Mesoblast Limited (ASX: MSB)
Mesoblast Limited (ASX: MSB), in its presentation on 27 February 2025, reported significant progress in its financial performance and clinical advancements for the half-year ended December 31, 2024. The company has maintained its position as a global leader in allogeneic cellular medicines for inflammatory diseases, with a strong presence in Australia, the United States, and Singapore. A major milestone was the FDA approval of RYONCIL, the first off-the-shelf mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD), which is now available for use in U.S. hospitals. This approval resulted in a $23 million reversal of inventory provisions from prior periods, reflecting its recognition as a valuable inventory asset.
Mesoblast strengthened its cash position, with a balance of US$38 million as of December 31, 2024. Net operating cash outflow was reduced by 22% compared to the previous year, demonstrating improved financial efficiency.
Mesoblast continues to expand its clinical pipeline. The company is advancing its Phase 3 trials for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with long-term pain reduction benefits observed in clinical studies. Additionally, Mesoblast is progressing regulatory efforts for REVASCOR, a treatment for heart failure with reduced ejection fraction (HFrEF). The FDA has granted the therapy Rare Pediatric Disease Designation, Regenerative Medicine Advanced Therapy designation, and Orphan Drug Designation for hypoplastic left heart syndrome. This recognition strengthens Mesoblast’s pathway toward accelerated approval.
The company is also focusing on label expansion strategies for RYONCIL, particularly for inflammatory bowel disease and adult SR-aGvHD patients who fail second-line treatments. In collaboration with the Blood and Marrow Transplant Clinical Trials Network, Mesoblast aims to initiate a Phase 3 trial for adults with SR-aGvHD. The company anticipates further regulatory approvals and pipeline advancements over the next six to twelve months, reinforcing its commitment to bringing innovative cellular medicines to market. With a strong financial position, ongoing clinical progress, and a clear regulatory strategy, Mesoblast is well-positioned for long-term growth and leadership in the field of regenerative medicine.
(Source: Company's Report)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
